Stephen L. Rawlings

Array ( [id] => 10784201 [patent_doc_number] => 20160130356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/987432 [patent_app_country] => US [patent_app_date] => 2016-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 76999 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14987432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980039 [patent_doc_number] => 20160176983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'INTERCALATED SINGLE-CHAIN VARIABLE FRAGMENTS' [patent_app_type] => utility [patent_app_number] => 14/971502 [patent_app_country] => US [patent_app_date] => 2015-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 18150 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14971502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12908998 [patent_doc_number] => 20180194841 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => METHODS FOR TUMOR TREATMENT USING CD3XCD20 BISPECIFIC ANTIBODY [patent_app_type] => utility [patent_app_number] => 15/527002 [patent_app_country] => US [patent_app_date] => 2015-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15527002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17378142 [patent_doc_number] => 11236139 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Combination immunotherapy [patent_app_type] => utility [patent_app_number] => 15/524740 [patent_app_country] => US [patent_app_date] => 2015-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 17 [patent_no_of_words] => 36343 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806562 [patent_doc_number] => 20160152720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND TIGIT INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/927110 [patent_app_country] => US [patent_app_date] => 2015-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 42679 [patent_no_of_claims] => 68 [patent_no_of_ind_claims] => 42 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14927110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10792975 [patent_doc_number] => 20160139131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-19 [patent_title] => 'ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 14/918490 [patent_app_country] => US [patent_app_date] => 2015-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 28950 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14918490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11948282 [patent_doc_number] => 20170252433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'PSMA-RELATED THERAPIES' [patent_app_type] => utility [patent_app_number] => 15/518010 [patent_app_country] => US [patent_app_date] => 2015-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 12486 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15518010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001889 [patent_doc_number] => 20170306044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1 FOR USE IN THE TREATMENT OF OVARIAN CANCER' [patent_app_type] => utility [patent_app_number] => 15/517329 [patent_app_country] => US [patent_app_date] => 2015-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 26807 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15517329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001863 [patent_doc_number] => 20170306018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1' [patent_app_type] => utility [patent_app_number] => 15/517296 [patent_app_country] => US [patent_app_date] => 2015-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 36501 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15517296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693787 [patent_doc_number] => 20160039933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'ANTIBODIES SPECIFIC TO CADHERIN-17' [patent_app_type] => utility [patent_app_number] => 14/875285 [patent_app_country] => US [patent_app_date] => 2015-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 50874 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14875285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11987792 [patent_doc_number] => 20170291946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-12 [patent_title] => 'MODULATION OF STIMULATORY AND NON-STIMULATORY MYELOID CELLS' [patent_app_type] => utility [patent_app_number] => 15/514471 [patent_app_country] => US [patent_app_date] => 2015-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 58 [patent_no_of_words] => 47186 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15514471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11942126 [patent_doc_number] => 20170246277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'REAGENTS AND METHODS FOR IDENTIFYING, ENRICHING, AND/OR EXPANDING ANTIGEN-SPECIFIC T CELLS' [patent_app_type] => utility [patent_app_number] => 15/512234 [patent_app_country] => US [patent_app_date] => 2015-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19738 [patent_no_of_claims] => 83 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15512234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12200810 [patent_doc_number] => 09903872 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-27 [patent_title] => 'Identification of protein associated with hepatocellular carcinoma, gliobastoma and lung cancer' [patent_app_type] => utility [patent_app_number] => 14/850358 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 32609 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14850358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11956109 [patent_doc_number] => 20170260261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'Conditionally Active Chimeric Antigen Receptors for Modified T-Cells' [patent_app_type] => utility [patent_app_number] => 15/504470 [patent_app_country] => US [patent_app_date] => 2015-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 41787 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15504470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15726785 [patent_doc_number] => 10611814 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-07 [patent_title] => Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders [patent_app_type] => utility [patent_app_number] => 15/504012 [patent_app_country] => US [patent_app_date] => 2015-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 11177 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15504012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11837869 [patent_doc_number] => 20170219588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'METHOD OF SCREENING OF COMPOUNDS USING MEMBRANE STIM1' [patent_app_type] => utility [patent_app_number] => 15/424357 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5546 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15424357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866207 [patent_doc_number] => 20170233492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'HUMAN ANTIBODY SPECIFIC TO C-MET AND PREPARATION METHOD THEREOF' [patent_app_type] => utility [patent_app_number] => 15/501843 [patent_app_country] => US [patent_app_date] => 2015-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7820 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15501843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460801 [patent_doc_number] => 10844136 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same [patent_app_type] => utility [patent_app_number] => 15/327369 [patent_app_country] => US [patent_app_date] => 2015-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 39 [patent_no_of_words] => 19171 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15327369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11668508 [patent_doc_number] => 20170157228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'Immunogenic Polypeptide Composed of HLA-B7 Restricted Tumor Antigen-Derived Optimized Cryptic Peptides, and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/327244 [patent_app_country] => US [patent_app_date] => 2015-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4943 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15327244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16215154 [patent_doc_number] => 10730952 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-04 [patent_title] => Molecules with specificity for CD45 and CD79 [patent_app_type] => utility [patent_app_number] => 15/326499 [patent_app_country] => US [patent_app_date] => 2015-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 40194 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15326499 [rel_patent_id] =>[rel_patent_doc_number] =>)